|
Back to Home » August 2019 News » OxThera Receives Positive Decision From EMA on Paediatric Investigational Plan (PIP) for Treatment of Primary Hyperoxaluria With Oxalobacter formigenes |
OxThera Receives Positive Decision From EMA on Paediatric Investigational Plan (PIP) for Treatment of Primary Hyperoxaluria With Oxalobacter formigenes |
August 23, 2019
STOCKHOLM, Sweden, Aug. 23, 2019 /PRNewswire/ -- OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), today announced that, based on a positive opinion from the Paediatric Committee (PDCO), the EMA has agreed to...
Source URL: https://www.prnewswire.com:443/news-releases/oxthera-receives-positive-decision-from-ema-on-paediatric-investigational-plan-pip-for-treatment-of-primary-hyperoxaluria-with-oxalobacter-formigenes-300905995.html
|
|
|
|
